Fig. 1From: Real-world effectiveness of omalizumab for severe allergic asthma treatment in ColombiaChange of number of clinically significant asthma exacerbations, hospitalizations and emergency visits after starting omalizumab (time 0), at 6 months (time 1), and at 12 months (time 2). Boxes show the annualized rate of clinically significant asthma exacerbations, hospitalizations and emergency visits. Panel A: patients ≥ 18 years old. Panel B: patients < 18 years old. A significant reduction was found in the three outcomes at times 1 and 2Back to article page